Home›Oncology› SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysis
SGLT2 inhibitors not tied to gastrointestinal cancer risk in type 2 diabetes meta-analysisSGLT2 inhibitors show no link to gastrointestinal cancer risk
Clinical and experimental medicinePublished September 6, 2026Study authors: Zhang Yu-Fan, Xie Jia-Jie, Wu Qi, Zhou Xiao-Yu, Zeng Chen, Zeng Yan, He Yi-Meng, Guo Man, Teng Fang-…PubMed ↗DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret the absence of increased GI neoplasm risk with SGLT2 inhibitors as reassuring but not definitive.
This meta-analysis pooled data from 48,765 patients with type 2 diabetes mellitus to evaluate the association between SGLT2 inhibitor therapy and the risk of gastrointestinal (GI) neoplasms. The analysis included trials with placebo or active comparators, and the primary outcome was overall GI neoplasm risk, with secondary outcomes covering esophageal, gastric, hepatic, pancreatic, colonic, colorectal, and rectal neoplasms.
For the primary outcome, the pooled odds ratio was 1.10 (95% CI: 0.84-1.44; p = 0.46), indicating no statistically significant increase in overall GI neoplasm risk. Site-specific analyses similarly showed no significant associations: esophageal (OR 1.12, 95% CI 0.37-3.45), gastric (OR 1.20, 95% CI 0.65-2.23), hepatic (OR 0.62, 95% CI 0.31-1.22), pancreatic (OR 0.91, 95% CI 0.51-1.64), colonic (OR 1.28, 95% CI 0.78-2.08), colorectal (OR 0.76, 95% CI 0.27-2.17), and rectal (OR 0.98, 95% CI 0.49-1.97). All p-values were >0.05.
The authors describe these findings as reassuring but not definitive. Limitations include limited follow-up (approximately half of the trials had follow-up of one year or less), low event counts, and non-cancer-specific outcome ascertainment. These factors preclude firm conclusions about long-term oncologic safety.
For clinicians, this evidence does not suggest a clear increase in GI neoplasm risk with SGLT2 inhibitors in type 2 diabetes, but it should not be interpreted as proof of long-term safety. Continued pharmacovigilance and longer-term studies are warranted.
How this fits prior evidence
This meta-analysis extends prior coverage of SGLT2 inhibitors in type 2 diabetes by addressing a potential oncologic concern. Earlier findings showed benefits for diabetic retinopathy progression (RR 0.77) and macular edema (RR 0.75), as well as superior glycemic control and weight loss versus DPP-4 inhibitors. The current analysis found no significant association with GI neoplasm risk (OR 1.10, 95% CI 0.84-1.44), which is consistent with the overall safety profile but does not confirm long-term safety due to short follow-up and low event counts.
People living with type 2 diabetes often have to weigh the benefits of new medications against potential long-term risks. One common concern has been whether SGLT2 inhibitors—a class of drugs used to manage blood sugar—might increase the risk of developing cancers in the digestive tract, such as those in the stomach, liver, or colon.
A large review of data from over 48,000 patients looked specifically at this link. The researchers found no significant association between taking SGLT2 inhibitors and an increased risk of gastrointestinal neoplasms, which is the medical term for tumors or growths. This included specific checks on cancers of the esophagus, stomach, liver, pancreas, colon, and rectum.
While these results are encouraging, the findings are not definitive. Many of the trials included in the review had short follow-up periods of one year or less, and the total number of cancer events reported was low. Because of these limitations, the data provides a reassuring look at safety but does not offer a long-term guarantee. Talk with your doctor to see how these findings fit into your specific treatment plan.
What this means for you:
SGLT2 inhibitors do not appear to increase the risk of gastrointestinal cancers in people with type 2 diabetes.
Common questions
Do SGLT2 inhibitors cause stomach or colon cancer?
The study of 48,765 patients found no statistically significant association between SGLT2 inhibitor therapy and gastrointestinal neoplasms. This includes specific types like colonic, colorectal, and rectal neoplasms. While the results are reassuring, the study notes that the evidence is not definitive because many trials had follow-up periods of one year or less.
Is it safe to take SGLT2 inhibitors for type 2 diabetes?
The data suggests that SGLT2 inhibitors are not associated with an increased risk of gastrointestinal tumors in patients with type 2 diabetes. However, because the study had low event counts and limited follow-up times, it does not provide a definitive long-term safety guarantee. You should discuss your specific health needs and treatment plan with your doctor.
What specific types of digestive cancers were checked?
The analysis looked at several specific types of gastrointestinal neoplasms. These included esophageal, gastric, hepatic, pancreatic, colonic, colorectal, and rectal neoplasms. In every category checked, the study found no statistically significant association with the use of SGLT2 inhibitors.
The potential carcinogenic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) remain controversial, particularly regarding site-specific gastrointestinal (GI) neoplasms. This systematic review and meta-analysis aimed to determine the relationship between SGLT2 inhibitors and the risk of GI neoplasms in patients with T2DM. We searched PubMed, EMBASE, Cochrane CENTRAL, Scopus, and Web of Science through March 17, 2025, for RCTs in T2DM comparing SGLT2 inhibitors with placebo or active comparators. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. The primary outcome was GI neoplasms reported in publications, supplementary materials, or trial registries, usually as adverse events rather than centrally adjudicated cancer endpoints. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated in Stata 17.0. In 48 RCTs (n = 48,765), SGLT2 inhibitor therapy was not associated with overall GI neoplasm risk (OR = 1.10, 95% CI: 0.84-1.44; p = 0.46; I² = 0%). Site-specific analyses showed no statistically significant association for esophageal (OR = 1.12, 95% CI 0.37-3.45), gastric (1.20, 0.65-2.23), hepatic (0.62, 0.31-1.22), pancreatic (0.91, 0.51-1.64), colonic (1.28, 0.78-2.08), colorectal (0.76, 0.27-2.17), and rectal neoplasms (0.98, 0.49-1.97), with all p-values > 0.05. Subgroup analyses by agents (e.g., canagliflozin, dapagliflozin, empagliflozin), baseline age, body mass index (BMI), HbA1c, treatment duration, and dose were also non-significant (all p > 0.05). Approximately half of the trials had follow-up of one year or less, limiting our ability to evaluate long-term risk. Available RCT evidence does not show a clear increase in GI neoplasm risk with SGLT2 inhibitors in T2DM. However, limited follow-up, low event counts, and non-cancer-specific outcome ascertainment, the findings should be interpreted as reassuring but not definitive evidence of long-term oncologic safety.Systematic review registration: PROSPERO No. CRD42024619019.
